London, UK: In a new study conducted by Sofia Ajamil-Rodanes and team it was found that intravitreal implant (Iluvien) may have a therapeutic impact in the treatment of Birdshot-related vascular leakage, cystoid macular edema (CMO), and retinal impairment. Choroidal lesions, on the other hand, appear to persist with no discernible response to therapy. The findings of this study were published in the British Journal of Ophthalmology.
The purpose of this study was to report on the treatment results and efficacy of the fluocinolone acetonide 0.19 mg Iluvien in reducing retinal and choroidal inflammation in 11 patients with birdshot retinochoroiditis.
This was a retrospective, interventional case series from a single center. Improvement in vascular leakage on fluorescein angiography (FA), effect on CMO, and resolution of hypo fluorescent lesions on indocyanine green angiography (ICGA) was the primary efficacy endpoints; secondary measures included improvements in pattern and full-field electroretinogram (PERG; ERG) parameters. Intraocular elevation and cataractogenesis were used as safety outcome metrics.
The key findings of this study were as follow:
1. With an average follow-up of 31 months (range 12–36 months), 15 eyes got Iluvien implants.
2. Prior to the implant, 5 (33.3%) of the eyes had received 0.7 mg dexamethasone intravitreal implant (Ozurdex).
3. At baseline, FA exhibited indications of vascular leakage in all eyes. FA revealed that 73.4 percent of eyes had no leakage during months 6 and 12, increasing to 84.6% by month 24.
4. CMO was present in three of the eyes in our investigation at the start. All eyes had perfect CMO resolution 6 months following the Iluvien implant.
5. The distinctive hypo fluorescent lesions on ICGA remained constant one year after implant implantation in all instances.
6. There was baseline ERG evidence of a high prevalence of peripheral cone system malfunction, and the majority of patients had PERG evidence of macular dysfunction.
7. Following therapy, the majority of patients' retinal and macular functions improved or remained constant.
Reference:
Ajamil-Rodanes S, Testi I, Luis J, et al, Evaluation of fluocinolone acetonide 0.19 mg intravitreal implant in the management of birdshot retinochoroiditis, British Journal of Ophthalmology 2022;106:234-240. doi:10.1136/bjophthalmol-2021-320961